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Abstract
The tight-skin (TSK/+) mouse, a genetic model of systemic
sclerosis (SSc), develops cutaneous fibrosis and defects in
pulmonary architecture. Because hepatocyte growth factor
(HGF) is an important mitogen and morphogen that contributes
to the repair process after tissue injury, we investigated the role
of HGF in cutaneous fibrosis and pulmonary architecture
defects in SSc using TSK/+ mice. TSK/+ mice were injected in
the gluteal muscle with either hemagglutinating virus of Japan
(HVJ) liposomes containing 8 μg of a human HGF expression
vector (HGF-HVJ liposomes) or a mock vector (untreated
control). Gene transfer was repeated once weekly for 8 weeks.
The effects of HGF gene transfection on the histopathology and
expression of tumor growth factor (TGF)-β and IL-4 mRNA in
TSK/+ mice were examined. The effect of recombinant HGF on
IL-4 production by TSK/+ CD4+ T cells stimulated by allogeneic
dendritic cells (DCs) in vitro was also examined. Histologic
analysis revealed that HGF gene transfection in TSK/+ mice
resulted in a marked reduction of hypodermal thickness,
including the subcutaneous connective tissue layer. The
hypodermal thickness of HGF-treated TSK/+ mice was
decreased two-fold to three-fold compared with untreated TSK/
+ mice. However, TSK/+ associated defects in pulmonary
architecture were unaffected by HGF gene transfection. HGF
gene transfection significantly inhibited the expression of IL-4
and TGF-β1 mRNA in the spleen and skin but not in the lung.
We also performed a mixed lymphocyte culture and examined
the effect of recombinant HGF on the generation of IL-4.
Recombinant HGF significantly inhibited IL-4 production in
TSK/+ CD4+ T cells stimulated by allogeneic DCs. HGF gene
transfection inhibited IL-4 and TGF-β mRNA expression, which
has been postulated to have a major role in fibrinogenesis and
reduced hypodermal thickness, including the subcutaneous
connective tissue layer of TSK/+ mice. HGF might represent a
novel strategy for the treatment of SSc.
Introduction
Systemic sclerosis (SSc) is a connective tissue disorder of
unknown etiology that is characterized by an excessive depo-
sition of extracellular matrix protein in the affected skin, in addi-
tion to various internal organs. Currently, no effective therapies
for SSc exist [1]. The tight-skin (TSK/+) mouse is a genetic
model for human SSc. Although the phenotypic characteris-
tics of the TSK/+ mouse are not identical to those of human
SSc patients, TSK/+ mice produce autoantibodies against
SSc-specific autoantigens, including topo-I, fibrillin 1 (fbn-1),
collagen type 1, and Fcγ receptors [2,3]. The gene defect
responsible for the TSK/+ phenotype in mice is yet to be defin-
itively identified; however, the fbn-1 gene has been recently
proposed as a candidate locus for this disorder [4]. The fbn-1
gene mutation seems to provide an explanation for the embry-
onic lethality of homozygous tight skin (TSK/TSK) animals.
Heterozygous (TSK/+) mice, which have a normal lifespan,
exhibit fibrosis and thickening of subcutaneous dermal tissue.
Other abnormalities in TSK/+ mice include increased lung col-
lagen content, enlarged air spaces reminiscent of pulmonary
CD4-/- = CD4 knockout; DC = dendritic cell; ELISA = enzyme-linked immunosorbent assay; fbn-1 = fibrillin 1; GVHD = graft-versus-host disease; 
HGF = hepatocyte growth factor; HSCT = hematopoietic stem-cell transplantation; HVJ = hemagglutinating virus of Japan; IFN = interferon; IL = 
interleukin; IL-4 receptor alpha = IL-4Rα; mAb = monoclonal antibody; MLR = mixed lymphocyte reaction; pa/pa = homozygous pallid; PCR = 
polymerase chain reaction; RT = reverse transcriptase; SSc = systemic sclerosis; TGF = tumor growth factor; TSK/TSK = homozygous tight skin; 
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emphysema, and, with advanced age, development of pro-
gressive myocardial fibrosis and hypertrophy [5-7].
Hepatocyte growth factor (HGF) was originally identified and
cloned as a potent mitogen for hepatocytes [8,9]. It has
mitogenic, motogenic, and morphogenic effects on various
epithelial tissues, including the liver, kidneys, lungs, and intes-
tines [10-12]. HGF also shows antiapoptotic activity [13] and
has a role in suppressing fibrosis in the liver [14]. HGF might,
therefore, induce tissue repair in dermal sclerosis associated
with SSc. We recently demonstrated that repeated transfec-
tion of the human HGF gene into skeletal muscle induced con-
tinuous production of HGF, strongly inhibited acute graft-
versus-host disease (GVHD) after allogeneic hematopoietic
stem-cell transplantation (HSCT), and protected against
thymic damage caused by GVHD in a well-characterized
mouse model of GVHD [15,16]. The present study was per-
formed to examine the therapeutic effect of HGF on tissue
fibrosis in TSK/+ mice.
Materials and methods
Animals
TSK/+ and homozygous pallid (pa/pa) mutant mice with a
C57BL/6 background were obtained from the Jackson Labo-
ratory (Bar Harbor, ME, USA). TSK/+ mice are heterozygous
for both TSK and pa gene mutations. TSK/+ mice were pro-
duced by mating TSK/+ male mice with pa/pa female mice.
TSK/+ progeny were identified by their back-coat and eye
colors, in addition to their characteristic loss of skin pliability.
To verify the TSK/+ genotype, PCR amplification of a partially
duplicated fbn-1 gene was carried out using genomic DNA
from each mouse, as described previously [17]. C57BL/6 and
(C57BL/6 × DBA/2)F1 (BDF1) mice were obtained from the
Shizuoka Laboratory Animal Center (Hamamatsu, Shizuoka,
Japan). All mice were maintained in a pathogen-free facility at
the Hyogo College of Medicine (Nishinomiya, Hyogo, Japan).
Animal experiments were performed in accordance with the
guidelines of the National Institutes of Health (Bethesda, MD,
USA), as specified by the animal care policy of Hyogo College
of Medicine.
Expression vector and preparation of liposomes 
containing hemagglutinating virus of Japan (HVJ)
Human HGF cDNA (2.2 kb) was inserted into the EcoRI and
NotI sites of the pUC-SRα plasmid under control of the
cytomegalovirus enhancer-promoter [18]. HVJ liposomes con-
taining plasmid DNA and high mobility group 1 protein were
constructed, as described previously [15,16]. Briefly, phos-
phatidylserine, phosphatidylcholine, and cholesterol were
mixed at a weight ratio of 1 : 4.8 : 2. This lipid mixture (1 mg)
plus plasmid DNA (20–40 μg), which had previously been
complexed with 6–12 μg of high mobility group 1 nonhistone
chromosomal protein purified from calf thymus, were soni-
cated to form liposomes and then mixed with ultraviolet-irradi-
ated HVJ. Excess free virus was subsequently removed from
the HVJ liposomes by sucrose-density-gradient centrifugation.
Gene transfer
TSK/+ mice were injected in the gluteal muscle with either
HVJ liposomes containing 8 μg of the human HGF expression
vector (HGF-HVJ liposomes) or mock vector (untreated con-
trol). Gene transfer was repeated once weekly for 8 weeks.
Histopathology
Tissues were fixed in 10% buffered formalin and embedded in
paraffin. Sections were stained with hematoxylin and eosin
and were examined by light microscopy.
RT-PCR
RNA was extracted using an Isogen (Nippongene, Toyama,
Japan) kit, according to the manufacturer's instructions, and
cDNA was prepared using 2.5 μM random hexamers (Applied
Biosystems Inc., Foster City, CA, USA). IL-4 and TGF-β mRNA
levels were quantified by real-time RT-PCR in a total volume of
25 μl for 40–50 cycles of 15 seconds at 95°C and 40–50
cycles of 1 minute at 60°C. Samples were run in triplicate and
relative expression levels were determined by normalizing
expression levels to that of β-actin. The primer sequences
used were as follows:
1. IL-4, CCAGCTAGTTGTCATCCTGCTCTTCTTTCTCG
and CAGTGATGAGGACTTGGACTCATTCATGGTGC.
2. TGF-β1, TGGACCGCAACAACGCCATCTATGA-
GAAAACC and TGGAGCTGAAGCAATAGTTGGTATC-
CAGGGCT.
3. β-actin, TGTGATGGTGGGAATGGGTCAG and TTTGAT-
GTCACGCACGATTTCC.
Mixed lymphocyte reaction (MLR) and in-vitro cytokine 
production
CD4+ T cells and CD11c+ dendritic cells (DCs) were purified
from spleen cells using immunomagnetic beads (Miltenyi Bio-
tec, CA, USA). The purity of the CD4+ and CD11c+ cell popu-
lations was >90% and >95%, respectively. CD4+ T cells from
TSK/+ (H-2b) mice (4 × 106 cells/ml/well) were cultured with
irradiated (20 Gy) CD11c+ DCs from BDF1 (H-2b × d) mice (1
× 106 cells/ml/well) in 24-well flat-bottomed plates (Falcon
Labware, Lincoln Park, NJ, USA). After 72 hours, viable cells
(1 × 105 cells/200 μl/well) were stimulated in 96-well flat-bot-
tomed plates (Falcon Labware) coated with 5 μg/ml anti-CD3
mAb. After 48 hours, IL-4 and IFN-γ concentrations in the cul-
ture supernatants were measured by ELISA.
ELISA for IL-4
The levels of murine IL-4 in culture supernatants were meas-
ured by ELISA using antimouse IL-4 mAb (Genzyme Pharma-Available online http://arthritis-research.com/content/8/6/R161
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ceuticals, Cambridge, MA, USA) according to the
manufacturer's protocol.
Statistical analysis
Group mean values were compared by the two-tailed Stu-
dent's t-test. A p value of < 0.05 was considered statistically
significant.
Results
Prevention of scleroderma by HGF gene transfection
We previously reported that repeated transfection of the
human HGF gene into skeletal muscle of allogeneic HSCT
recipients reduced the tissue damage and subsequent inflam-
matory responses caused by acute GVHD [15,16]. To investi-
gate the possible therapeutic effects of HGF on SSc, young
TSK/+ mice were treated with HGF gene transfection. Treat-
ment consisted of once-weekly intramuscular injection of
either HGF-HVJ liposomes or control mock vectors for a
period of 8 weeks (Figure 1). Histologic analysis revealed that
HGF treatment of TSK/+ mice resulted in a marked reduction
of hypodermal thickness, including the subcutaneous connec-
tive tissue layer (Figure 2). Skin fibrosis was assessed quanti-
tatively by measuring hypodermal thickness. The hypodermal
thickness of HGF-treated TSK/+ mice was decreased two-
fold to three-fold compared with untreated TSK/+ mice (Fig-
ure 3).
Effect of HGF gene transfection on pulmonary changes
The effect of HGF gene transfection on pulmonary changes
was examined. Control mock-vector-transfected TSK/+ mice
all displayed a markedly dilated alveolar space, with fewer
alveolar walls compared with pa/pa mice. This TSK/+-associ-
ated abnormality in lung architecture was unaffected by HGF
gene transfection (Figure 4).
Effect of HGF on the expression of IL-4 and TGF-β mRNA 
expression and production
IL-4 and TGF-β have been postulated to have major roles in
fibrinogenesis in animal models [19-23]. To clarify whether
modulation of IL-4 and TGF-β has a role in the prevention of
sclerosis induced by HGF gene transfection in the sclero-
derma model mouse, we examined the mRNA expression of
these cytokines. HGF gene transfection significantly inhibited
the expression of IL-4 and TGF-β1 mRNA in the spleen and
skin but not in the lung (Figure 5). We also performed MLR
and examined the effect of HGF on the production of IL-4.
Responder CD4+ T cells from TSK/+ mice were cultured with
irradiated (20 Gy) CD11c+ DCs from BDF1 mice with or with-
out recombinant HGF. After 3 days' culture, viable cells were
stimulated by culture with anti-CD3 mAb for 48 hours and the
IL-4 level in the culture supernatant was assayed by ELISA.
HGF significantly inhibited IL-4 production from TSK/+ CD4+
T cells stimulated by BDF1 DCs (Figure 6).
Discussion
SSc is an autoimmune connective tissue disease that is char-
acterized by microvascular damage, extracellular matrix depo-
sition, and fibrosis. There is no completely effective treatment
for this disease at present. We previously demonstrated that
serum HGF levels were significantly elevated in patients with
SSc and serum HGF levels correlated to markers of endothe-
lial injury (thrombomodulin) and interstitial lung injury (KL-6),
suggesting that elevation of serum HGF counteracts the
endothelial and interstitial lung injury caused by SSc [24]. The
serum level of HGF is significantly elevated in various dis-
eases, depending on the severity of the disease [25-27]. How-
ever, endogenously induced HGF is not sufficient to repair
tissue injuries, and, therefore, supplementation with exoge-
nous HGF is necessary to accelerate the tissue repair process
in animal models [14,15,28]. In the present study, we
assessed the effect of exogenous HGF on skin fibrosis and the
development of pulmonary defects in the TSK/+ mouse model
of SSc. Both our present study and other previous studies [5]
have shown that dermal thickness is similar in TSK/+ and wild-
type littermates, but hypodermal thickness, including the sub-
cutaneous connective tissue layer, is significantly increased in
TSK/+ mice compared with wild-type littermates. HGF gene
transfection of TSK/+ mice for a period of 8 weeks resulted in
a marked reduction of hypodermal thickness, including the
subcutaneous connective tissue layer. Although the therapeu-
tic effect of HGF is not significant, we also observed the
reduction of hypodermal thickness in TSK/+ mice following
HGF  gene transfection for a period of 4 weeks (data not
shown).
Although the cause of SSc is unknown, IL-4 and TGF-β have
been postulated to have major roles in fibrinogenesis. In one
study, intravenously administered human immunoglobulin
decreased splenocyte secretion of IL-4 and TGF-β, which
resulted in abrogation of fibrinogenesis in TSK/+ mice and,
Figure 1
Experimental protocol for injection of HGF-HVJ liposomes into TSK/+  mice Experimental protocol for injection of HGF-HVJ liposomes into TSK/+ 
mice. Treatment consisted of once-weekly injection of either HGF-HVJ 
liposomes or control mock vector for a period of 8 weeks. Treatment 
was initiated at the age of 4 weeks. Histopathology and cytokine mRNA 
expression in the spleen, skin, and lungs was examined 8 weeks after 
treatment. HGF, hepatocyte growth factor; HVJ, hemagglutinating virus 
of Japan; im, intramuscular; TSK/+, tight skin.Arthritis Research & Therapy    Vol 8 No 6    Iwasaki et al.
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consequently, prevented the accumulation of fibrous tissue
[19]. Furthermore, administration of an anti-IL-4 or anti-TGF-β
antibody prevented dermal collagen deposition in TSK/+ mice
and murine sclerodermatous GVHD, respectively [20,21]. In
the present study, HGF treatment also reduced expression of
both IL-4 and TGF-β mRNA in the spleen and skin.
IL-4 regulates collagen and extracellular matrix production by
fibroblasts [22,23]. TSK/+ mice exhibiting disrupted genes
encoding IL-4 receptor alpha (IL-4Rα) or IL-4 lacked skin scle-
rosis [17,29], suggesting that IL-4 has a crucial role in skin
sclerosis in TSK/+ mice. A primary source of IL-4 in vivo is
CD4+ T cells [30] and a previous study demonstrated that
CD4+ T cells were essential to the TSK/+ phenotype, because
a lack of these cells prevented development of dermal thicken-
ing [31]. Therefore, we examined the effect of HGF on the
generation of IL-4 from CD4+ T cells. HGF significantly inhib-
ited IL-4 production from CD4+ T cells stimulated by alloge-
neic DCs, suggesting that HGF inhibits dermal fibrosis, in part,
by inhibiting IL-4 production by CD4+ T cells.
We also observed downregulation of TGF-β1 mRNA expres-
sion in TSK/+ mice by HGF gene transfection. TGF-β1 has a
role in the induction of fibrosis, and HGF gene transfection
inhibited the production of TGF-β1 from macrophage-like cells
and fibroblastic cells [32]. Downregulation of TGF-β1 expres-
sion and inhibition of fibrosis by HGF were noted in a rat model
of liver cirrhosis [14] and a mouse model of chronic renal fail-
ure [33]. Recently, HGF has been shown to downregulate
TGF-β1 expression and prevent dermal sclerosis in a murine
bleomycin-induced scleroderma model [34]. The authors
observed that HGF gene transfection significantly reduced
both the expression of TGF-β1 mRNA and the production of
TGF-β1 by fibroblastic cells and macrophage-like cells that
infiltrated the dermis. Furthermore, HGF  gene transfection
prevented the symptoms of not only dermal sclerosis, but also
lung fibrosis induced by bleomycin injection.
By contrast, HGF gene transfection failed to alter the develop-
ment of pulmonary abnormalities in TSK/+ mice in our study.
The pathologic alteration of the lung structure of TSK/+ mice
represents pulmonary emphysema and is not related to hyper-
Figure 3
Effect of HGF on skin fibrosis in TSK/+ mice Effect of HGF on skin fibrosis in TSK/+ mice. Skin fibrosis was 
assessed by quantitatively measuring hypodermal thickness. The hypo-
dermal thickness was measured under light microscopy as the thick-
ness of the hypodermis or superficial fascia beneath the panniculus 
carnosus. Data represent the mean ± standard deviation from six mice 
(three male mice and three female mice) in each group. *p < 0.05. 
HGF, hepatocyte growth factor; TSK/+, tight skin.
Figure 2
Effect of HGF on skin fibrosis in TSK/+ mice Effect of HGF on skin fibrosis in TSK/+ mice. Skin fibrosis in dorsal skin from C57BL/6, pa/pa, and TSK/+ mice with or without treatment with HGF. 
Representative histologic sections stained with hematoxylin and eosin are shown (× 40). An asterisk indicates the subcutaneous loose connective 
tissue layer beneath the panniculus carnosus (arrow). HGF, hepatocyte growth factor; TSK/+, tight skin.Available online http://arthritis-research.com/content/8/6/R161
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synthesis of collagen that is similar to the pulmonary fibrosis
associated with SSc [35]. Apparently, emphysema in TSK/+
mice is not owing to the mutated fbn-1 gene that is responsi-
ble for the occurrence of cutaneous hyperplasia, because
transgenic mice bearing a mutated fbn-1  gene developed
cutaneous hyperplasia but did not exhibit pulmonary emphy-
sema [36]. Furthermore, TSK/+ mice exhibiting disrupted
genes encoding IL-4Rα, TGF-β, or IL-4 lacked skin sclerosis
but developed emphysema, indicating that different genes are
involved in the development of skin sclerosis and pulmonary
emphysema in TSK/+ mice [17,29]. Furthermore, other stud-
ies have shown that the pulmonary pathology remained
unchanged in TSK/+ CD4 knockout (CD4-/-) mice [31] and
TSK/+ mice treated with an anti-IL-4 antibody [20]. The dermal
and pulmonary components of the TSK/+ phenotype can,
therefore, be dissociated in vivo.
We used a transgenic approach instead of using a recom-
binant protein for the following reasons:
1. Because the half-life of a recombinant protein is quite short,
recombinant protein treatment needs an enormous dose of the
active form of HGF protein and frequent injections.
2. Administering a high dose of the active form of the HGF pro-
tein could cause adverse effects, such as tumorigenesis in
other organs [37].
3. Recombinant protein treatment is very costly.
By contrast, the transgenic approach is simple, safe, and
cheap and needs much less frequent injections. Repeated
weekly injection of HGF-HVJ liposomes achieves a continuous
high plasma level of HGF [14-16].
Although further studies are needed to fully explore the effects
of HGF on SSc, it is possible that HGF therapy might be a
promising strategy for the treatment of SSc.
Conclusion
HGF gene transfection of TSK/+ mice resulted in a marked
reduction of hypodermal thickness, including the subcutane-
ous connective tissue layer. However, TSK/+-associated
defects in pulmonary architecture were unaffected by HGF
gene transfection. HGF gene transfection significantly inhib-
ited the expression of IL-4 and TGF-β1 mRNA in the spleen
and skin but not in the lung. Recombinant HGF significantly
inhibited IL-4 production by TSK/+ CD4+ T cells stimulated by
allogeneic DCs. HGF might represent a novel strategy for the
treatment of SSc.
Figure 5
Effect of HGF on IL-4 and TGF-β1 mRNA expression in tight-skin mice Effect of HGF on IL-4 and TGF-β1 mRNA expression in tight-skin mice. 
Total RNA was isolated from the skin, spleen, and lung, and IL-4 and 
TGF-β1 mRNA expression was analyzed by RT-PCR assay. Data repre-
sent the mean ± standard deviation from five mice. *p < 0.05. HGF, 
hepatocyte growth factor; IL, interleukin; TGF, tumor growth factor.
Figure 4
Effect of HGF on pulmonary changes in TSK/+ mice Effect of HGF on pulmonary changes in TSK/+ mice. Representative histologic sections stained with hematoxylin and eosin are shown (× 40). HGF, 
hepatocyte growth factor; TSK/+, tight skin.Arthritis Research & Therapy    Vol 8 No 6    Iwasaki et al.
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